Consult
Log In
Menu
Consult
Log in

by Josh Forsythe, on March 16, 2018

Genetic diseases are the leading cause of death for infants in North America, affecting an estimated 4 percent of newborns. In MIT Technology Review, Rady Children’s Hospital in San Diego showcases the “new wave of precision medicine” that uses genetics to determine life saving drug options for newborns.

Read Story
Topics:News

by Josh Forsythe, on March 16, 2018

Laura J. Tafe, MD, associate professor of pathology and laboratory medicine at Geisel School of Medicine at Dartmouth, and assistant director of the Laboratory for Clinical Genomics and Advanced Technologies, Dartmouth-Hitchcock Medical Center, discusses a case of ALK-rearranged lung cancer, which was the subject of a multidisciplinary molecular tumor board presented last fall at the annual CAP meeting.

Read Story
Topics:News

by Josh Forsythe, on March 15, 2018

While healthcare continues to improve, advances in technologies and treatments have also made it more complex. It’s estimated that nearly 100,000 patients die every year due to medical errors [1]. And consider this: medical errors due to misdiagnosis account for up to 17% of all adverse medical events [2].

Read Story
Topics:News

by PierianDx, on March 14, 2018

by Brad Herrick, PierianDx

Read Story
Topics:News

by Josh Forsythe, on March 14, 2018

PierianDx, the leading genomics technology company that enables precision medicine programs and molecular testing for healthcare organizations, announced today a partnership with Cancer Genetics, Inc. (CGI) (Nasdaq: CGIX) to provide a comprehensive precision oncology testing and workflow solution to enhance patient care. CGI is a leader in enabling precision medicine for oncology through molecular markers and diagnostics.

Read Story
Topics:News

by Josh Forsythe, on March 8, 2018

PierianDx, the leading genomics technology company that enables precision medicine, announced today a full range of expanded services to support adoption of the company’s enterprise software platform, the Clinical Genomics WorkSpace (CGW).

Read Story
Topics:News

by Josh Forsythe, on February 18, 2018

PierianDx will be exhibiting at an intensive one-day summit for CEOs and hospital administrators of health systems. “Precision Medicine for Hospital CEOs: What You Need to Know about Genetic Testing, Precision Medicine, and Population Health Management” that takes place on Wednesday, February 21, at the Convene Cira Center in Philadelphia. The summit features workshops by two PierianDx customers, Inova Health and NorthShore University Health System.

Read Story
Topics:News

by Josh Forsythe, on February 13, 2018

PierianDx, the leading genomics technology company that enables precision medicine programs and molecular testing for healthcare organizations, announced today it will be hosting an expert panel to discuss CMS’s National Coverage Decision (NCD) on clinical tests that limit the coverage to FDA-approved NGS tests with companion diagnostic indications.

Read Story
Topics:News

by Josh Forsythe, on January 5, 2018

PharmaTech Outlook recently featured PierianDx in it’s December 2017 issue, outlining the groundbreaking role the company has played in advancing NGS testing and precision medicine for healthcare organizations. The article details the evolution of PierianDx’s solution offerings, from the core technology platform, the Clinical Genomics WorkSpace (CGW) supported by its robust knowledgebase, to the company’s addition of validation, interpretation and turnkey lab services.

Read Story
Topics:News

by Josh Forsythe, on October 26, 2017

PierianDx announced today two key additions that will expand the organization’s reach into health systems and global markets while deepening clinical expertise.

Read Story
Topics:News

by Josh Forsythe, on October 17, 2017

PierianDx announced today that Cleveland Clinic will utilize its integrated “one space” workflow and analysis solution, Clinical Genomicist Workspace (CGW), to advance precision medicine for patients.

Read Story
Topics:News

by Josh Forsythe, on October 11, 2017

PierianDx, the forerunner in clinical genomic analysis, interpretation and reporting, announced today it has launched a complete technology and medical interpretation solution to support Illumina’s TruSight Tumor 170 (TST170). PierianDx will feature TST170 in an upcoming webinar October 12, 2017, at 1 pm EST hosted by GenomeWeb.

Read Story
Topics:News